ATE170630T1 - Proteine mit geänderten epitopen und verfahren zur deren herstellung - Google Patents

Proteine mit geänderten epitopen und verfahren zur deren herstellung

Info

Publication number
ATE170630T1
ATE170630T1 AT92900779T AT92900779T ATE170630T1 AT E170630 T1 ATE170630 T1 AT E170630T1 AT 92900779 T AT92900779 T AT 92900779T AT 92900779 T AT92900779 T AT 92900779T AT E170630 T1 ATE170630 T1 AT E170630T1
Authority
AT
Austria
Prior art keywords
proteins
production
variants
modified epitopes
protein
Prior art date
Application number
AT92900779T
Other languages
English (en)
Inventor
Uffe Loevborg
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8205875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE170630(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE170630T1 publication Critical patent/ATE170630T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/38Products with no well-defined composition, e.g. natural products
    • C11D3/386Preparations containing enzymes, e.g. protease or amylase
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/38Products with no well-defined composition, e.g. natural products
    • C11D3/386Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38627Preparations containing enzymes, e.g. protease or amylase containing lipase
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/38Products with no well-defined composition, e.g. natural products
    • C11D3/386Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38645Preparations containing enzymes, e.g. protease or amylase containing cellulase
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/38Products with no well-defined composition, e.g. natural products
    • C11D3/386Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38654Preparations containing enzymes, e.g. protease or amylase containing oxidase or reductase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
AT92900779T 1990-12-05 1991-12-05 Proteine mit geänderten epitopen und verfahren zur deren herstellung ATE170630T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90610072 1990-12-05

Publications (1)

Publication Number Publication Date
ATE170630T1 true ATE170630T1 (de) 1998-09-15

Family

ID=8205875

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92900779T ATE170630T1 (de) 1990-12-05 1991-12-05 Proteine mit geänderten epitopen und verfahren zur deren herstellung

Country Status (11)

Country Link
EP (1) EP0561907B1 (de)
JP (3) JP3355186B2 (de)
KR (1) KR100237968B1 (de)
AT (1) ATE170630T1 (de)
AU (1) AU9052891A (de)
BR (1) BR9107206A (de)
CA (2) CA2095852C (de)
DE (1) DE69130113T2 (de)
DK (1) DK0561907T3 (de)
FI (1) FI932561A0 (de)
WO (1) WO1992010755A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4028592B2 (ja) * 1992-07-17 2007-12-26 ジェネンコー インターナショナル インコーポレイテッド 高アルカリ性セリンプロテアーゼ
AU3599895A (en) * 1994-10-14 1996-05-06 Chiron Mimotopes Pty Ltd Method and apparatus for efficient mimotope discovery
EP1017794A1 (de) 1997-02-06 2000-07-12 Novo Nordisk A/S Polypeptid-polymer-konjugate mit hinzugefügten oder entfernten bindungsgruppen
US6284246B1 (en) 1997-07-30 2001-09-04 The Procter & Gamble Co. Modified polypeptides with high activity and reduced allergenicity
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
JP2002507426A (ja) 1998-03-26 2002-03-12 ザ、プロクター、エンド、ギャンブル、カンパニー アミノ酸置換を有するセリンプロテアーゼ変異体
US6495136B1 (en) 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
EP1082443A1 (de) * 1998-03-26 2001-03-14 The Procter & Gamble Company Serinproteasevarianten mit deletierten und substituierten aminosäuren
US6936249B1 (en) 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6838269B1 (en) * 1998-04-15 2005-01-04 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6642011B2 (en) * 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US6461849B1 (en) * 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
DE69916306T2 (de) * 1998-10-30 2005-05-04 Novozymes A/S Niedrigallergene proteinvarianten
AU776910B2 (en) * 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
KR20020021397A (ko) * 1999-07-22 2002-03-20 데이비드 엠 모이어 규정된 에피토프 영역에 아미노산 결실 및 치환을 갖는서브틸리신 프로테아제 변이체
MXPA02000842A (es) 1999-07-22 2002-07-30 Procter & Gamble Conjugados de proteasa que tienen sitios de corte protegidos estericamente.
AU6085800A (en) 1999-07-22 2001-02-13 Procter & Gamble Company, The Subtilisin protease variants having amino acid substitutions in defined epitope regions
MXPA02000837A (es) * 1999-07-22 2002-07-30 Procter & Gamble Conjugados de proteasa que tienen regiones epitopes protegidas estericamente.
WO2001007576A2 (en) * 1999-07-22 2001-02-01 The Procter & Gamble Company Intramolecularly cross-linked subtilisin proteases having reduced immunogenicity
US6617135B1 (en) 1999-08-09 2003-09-09 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
DK1252192T3 (da) 2000-02-11 2006-11-20 Merck Patent Gmbh Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
WO2001083559A2 (en) * 2000-04-28 2001-11-08 Novozymes A/S Production and use of protein variants having modified immunogenecity
RU2272644C2 (ru) 2000-06-29 2006-03-27 Мерк Патент Гмбх Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
US7153818B2 (en) 2000-07-28 2006-12-26 Henkel Kgaa Amylolytic enzyme extracted from bacillus sp. A 7-7 (DSM 12368) and washing and cleaning agents containing this novel amylolytic enzyme
CA2424720C (en) * 2000-10-02 2012-04-03 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
KR100900176B1 (ko) 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술
DK1373296T3 (da) * 2001-03-23 2012-01-09 Procter & Gamble Proteiner, der frembringer et ændret immunogent respons, og fremgangsmåder til fremstilling og anvendelse deraf
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CA2446087C (en) 2001-05-03 2013-06-18 Stephen D. Gillies Recombinant tumor specific antibody and use thereof
EP1427756A1 (de) * 2001-09-04 2004-06-16 MERCK PATENT GmbH Modifiziertes menschliches wachstumshormon
BR0214650A (pt) 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
WO2003057246A1 (en) * 2001-12-31 2003-07-17 Genencor International, Inc. Proteases producing an altered immunological response and methods of making and using the same
CA2795814A1 (en) * 2001-12-31 2003-07-17 Genencor International, Inc. Proteases producing an altered immunogenic response and methods of making and using the same
CN101177675B (zh) 2002-02-08 2014-05-21 诺维信公司 肌醇六磷酸酶变体
EP1504089A2 (de) * 2002-05-16 2005-02-09 Alk Abell A/S Allergenmutanten
JP4694966B2 (ja) 2002-07-30 2011-06-08 ジェネンコー・インターナショナル・インク エアロゾル生成を低減する製剤
WO2004014938A2 (en) * 2002-08-09 2004-02-19 Xencor Thrombopoiesis-stimulating proteins having reduced immunogenicity
ATE494368T1 (de) 2002-10-01 2011-01-15 Novozymes As Polypeptide der gh-61-familie
JP4494977B2 (ja) 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Gd2に結合するマウス14.18抗体のヒト化抗体(h14.18)およびそのil−2融合タンパク質
WO2004078960A1 (en) 2003-02-26 2004-09-16 Genencor International, Inc. Amylases producing an altered immunogenic response and methods of making and using the same
EP2500423B1 (de) 2003-02-26 2015-06-17 Danisco US Inc. Amylasen, die eine veränderte immunogene Reaktion bewirken, und Verfahren zu ihrer Herstellung und Verwendung
US20060236414A1 (en) 2003-06-19 2006-10-19 Novozymes A/S Proteases and methods for producing them
CN102505007B (zh) 2003-06-19 2016-04-20 诺维信公司 蛋白酶
ES2358092T3 (es) 2003-10-10 2011-05-05 Novozymes A/S Variantes de proteasa.
JP4948174B2 (ja) 2003-10-16 2012-06-06 マイクロメット アクツィエン ゲゼルシャフト 多重特異的脱免疫cd3−結合物質
DK1699822T3 (da) 2003-12-30 2008-08-04 Merck Patent Gmbh IL-7-fusionsproteiner med antistofdele, fremstilling deraf og anvendelse deraf
WO2005063808A1 (en) 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
WO2005066339A2 (en) 2004-01-06 2005-07-21 Novozymes A/S Polypeptides of alicyclobacillus sp.
ATE443724T1 (de) 2004-01-22 2009-10-15 Merck Patent Gmbh Antikrebs-antikörper mit reduzierter komplementfixierung
ATE491025T1 (de) 2004-04-02 2010-12-15 Novozymes As Subtilasevarianten mit veränderter immunogenität
ES2380105T3 (es) 2004-06-21 2012-05-08 Novozymes A/S Proteasas de Nocardiopsis
EP2272964A3 (de) 2004-10-04 2011-08-31 Novozymes A/S Polypeptide mit Phytaseaktivität und dafür codierende Polynukleotide
AR050895A1 (es) 2004-10-04 2006-11-29 Novozymes As Polipeptidos que tienen actividad de fitasa y polinucleotidos que los codifican
ATE465176T1 (de) 2004-12-09 2010-05-15 Merck Patent Gmbh Il-7-varianten mit reduzierter immunogenität
US8119387B2 (en) 2005-08-16 2012-02-21 Novozymes A/S Polypeptides of strain Bacillus sp. P203
EP1940881B1 (de) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Zusammensetzungen mit spezies-kreuzspezifischen antikörpern und verwendungen davon
WO2007067473A2 (en) 2005-12-06 2007-06-14 Genencor International, Inc. Perhydrolase epitopes
WO2007071426A1 (en) 2005-12-21 2007-06-28 Micromet Ag Pharmaceutical compositions with resistance to soluble cea
CA2635623C (en) 2005-12-30 2015-02-17 Michael Super Anti-cd19 antibodies with reduced immunogenicity
ES2384055T3 (es) 2005-12-30 2012-06-28 Merck Patent Gmbh Variantes de la interleucina-12p40 con estabilidad mejorada
EP1998793A1 (de) 2006-03-22 2008-12-10 Novozymes A/S Verwendung von polypeptiden mit antimikrobieller wirkung
WO2007112739A1 (en) 2006-04-04 2007-10-11 Novozymes A/S Phytase variants
EP2261328B1 (de) 2006-12-21 2013-11-20 Novozymes A/S Lipase-varianten zur pharmazeutischen Verwendung
US8221743B2 (en) 2006-12-22 2012-07-17 Novozymes A/S Use of polypeptides against diseases caused by protozoans
DK2129781T3 (da) 2007-03-26 2014-03-31 Novozymes As Hafnia-phytase
WO2010034835A2 (en) 2008-09-26 2010-04-01 Novozymes A/S Hafnia phytase variants
CA2759333A1 (en) 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
AU2010314798B2 (en) 2009-11-05 2013-10-24 Teva Pharmaceuticals Australia Pty Ltd Treatment of cancer involving mutated KRAS or BRAF genes
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
EP3227341A1 (de) 2014-12-02 2017-10-11 CeMM - Forschungszentrum für Molekulare Medizin GmbH Anti-mutante calreticulin-antikörper und deren verwendung bei der diagnose und therapie von myeloiden malignomen
EP4196575A1 (de) 2020-08-13 2023-06-21 Novozymes A/S Phytasevarianten und polynukleotide zur codierung davon

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903068A (en) * 1972-12-26 1975-09-02 Us Health Education & Welfare Facile synthesis of human insulin by modification of porcine insulin
DK6488D0 (da) * 1988-01-07 1988-01-07 Novo Industri As Enzymer
DK316989D0 (da) * 1989-06-26 1989-06-26 Novo Nordisk As Enzymer

Also Published As

Publication number Publication date
JPH06502994A (ja) 1994-04-07
WO1992010755A1 (en) 1992-06-25
FI932561A7 (fi) 1993-06-04
FI932561L (fi) 1993-06-04
EP0561907A1 (de) 1993-09-29
DE69130113D1 (de) 1998-10-08
AU9052891A (en) 1992-07-08
DE69130113T2 (de) 1999-05-12
BR9107206A (pt) 1993-11-03
DK0561907T3 (da) 1999-05-31
KR100237968B1 (ko) 2000-01-15
EP0561907B1 (de) 1998-09-02
CA2095852A1 (en) 1992-06-06
CA2331936A1 (en) 1992-06-06
CA2095852C (en) 2001-05-08
FI932561A0 (fi) 1993-06-04
JP2002101880A (ja) 2002-04-09
JP2003174871A (ja) 2003-06-24
JP3355186B2 (ja) 2002-12-09
CA2331936C (en) 2007-07-31
JP3450840B2 (ja) 2003-09-29
KR930703610A (ko) 1993-11-30

Similar Documents

Publication Publication Date Title
ATE170630T1 (de) Proteine mit geänderten epitopen und verfahren zur deren herstellung
ATE68826T1 (de) Verfahren zur herstellung von reifem, menschlichem serum-albumin.
KR900009095A (ko) 합성 항원, 이의 제조방법 및 용도
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
CA2025598A1 (en) Chimaeric hepadnavirus core antigen proteins
DE69233204D1 (de) Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
DE69316405D1 (de) Verfahren zur fermentativen Herstellung von Aminosäuren
CA2290485A1 (en) Method for the production of non-immunogenic proteins
DE69406158D1 (de) Verfahren zur Herstellung von Olefinen mit endständigen Doppelbindungen
DE68919246D1 (de) Verfahren zur Herstellung von Aminosäuren.
DE69129899D1 (de) Verfahren zur Herstellung von D-Alpha-Aminosäuren
DE69627150T2 (de) Verfahren zur herstellung von gegen e.coli bakterien der familie cs4-cfa/1 gerichteten antikörpern
DE69220113D1 (de) Verfahren zur Herstellung von menschlichem Serum Albumin
ATE227307T1 (de) Verfahren zur herstellung modifizierten proteine
KR900012626A (ko) 하이브리드 단백질, 이의 생산방법 및 이를 함유하는 약제학적 조성물
AT384032B (de) Verfahren zur herstellung von polydispersen nativen pseudomonas-flagella(h)-antigenen (fag)
DE68926922D1 (de) Verfahren zur Herstellung von L-alpha-Aminosäuren
DE69431097D1 (de) Verfahren zur Herstellung von humanem Serumalbumin
DE3884324D1 (de) Verfahren zur Herstellung von menschlichen pro-apolipoprotein-A-I-ähnlichen Proteinen.
DE3884261D1 (de) Verfahren zur Herstellung von Fremdproteinen in Streptomyceten.
ATE81013T1 (de) Verfahren zur herstellung von faktor viii:cmangelplasma und ein so erhaltenes mangelplasma.
ATE110775T1 (de) Verfahren zur herstellung von hirudin.
RU94038045A (ru) Антитела, нуклеиновые кислоты, способы выделения гена, способ получения антитела, способы лечения, фармацевтическая композиция
DE68902379D1 (de) Verfahren zur herstellung von verbessertem proteinhydrolysat.
ATE76081T1 (de) Verfahren zur herstellung von dipeptiden mit nterminalen nichtproteinogenen aminosaeuren.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
RZN Patent revoked